home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search
prev / next | register for news alert 
 
 

Regulation Of Nitric Oxide Activity For Disease Treatment

 
  August, 1 2001 23:58

 
     
Indirectly regulating nitric oxide activity

Nitric oxide (NO) has been shown to have a role in a number of conditions, including diabetes, hypertension, cancer, and impotence. This signaling molecule is present at low levels in all parts of the body and is involved in many important functions, including control of blood flow, neurotransmission, and protection from bacterial infection. In pathological condition such as inflammation, however, NO levels increase and become detrimental.

One potential way to decrease NO levels for disease treatment is to inhibit the enzyme NO synthase, which is responsible for creating it. This enzyme uses the amino acid arginine to release NO, so potential inhibitors include molecules that look like arginine and are recognized and bound by the enzyme, but cannot be used to create NO. Efforts are currently being directed toward developing such inhibitors, but it turns out there are naturally-occurring compounds that do this job. The levels of these inhibitory compounds are regulated primarily by another enzyme, 'dimethylarginine dimethylaminohydrolase' (DDAH), which works to eliminate them. Inhibiting DDAH, therefore, would lead to increased levels of natural NO synthase inhibitors, which may represent a new tactic for treating diseases related to increased NO levels.

In the August issue of Nature Structural Biology (Vol. 8, No. 8, 01 Aug 2001, pages 679-683), Neil McDonald at the Imperial Cancer Research Fund in London and colleagues report the structure of the enzyme DDAH. They find that it looks similar to other enzymes that work on derivatives of arginine, and propose a reaction mechanism for how it works to eliminate the arginine-related NO synthase inhibitors. This structure provides a basis for designing inhibitors for this enzyme, potentially providing a new way of indirectly regulating NO activity.

Contact:

Dr. Neil Q. McDonald
Imperial Cancer Research Fund
Structural Biology Laboratory
44 Lincoln's Inn Fields
Rm315
Holborn
London, WC2A3PX
UK
Telephone #: +44 20 269 3259
Fax #: +44 20 269 3258
Email Address: n.mcdonald@icrf.icnet.uk

Nature Structural Biology press release.



Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
myExperiment.org: A repository of workflows in bioinformatics

A new program for the organization of pdf papers and references

Cone Starvation In Retinitis Pigmentosa

Seeing Cancer Specifics

Bringing Galatea To Life?

Blood Stem Cells Require Editing

Reviving Exhausted Immune Cells

New Inherited Factors Influencing Blood Lipid Levels

Melatonin And Risk Of Type 2 Diabetes

Cancer Stem Cells And Melanoma

Molecular Arms Race

Binding Too Tight

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2008 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.